Insilico Medicine, a global leader in artificial intelligence-driven drug discovery, has announced a multi-year collaboration with Servier, an independent international pharmaceutical company governed by a foundation. The strategic partnership focuses on identifying and developing novel therapeutics for difficult-to-treat targets in oncology, leveraging Insilico’s proprietary AI platform, Pharma.AI. Under the agreement, Insilico is eligible to receive up to $32 million in upfront and near-term research and development (R&D) payments. The company will lead the AI-powered discovery and early development of potential drug candidates that meet predefined criteria, while Servier will share R&D costs and take the lead in clinical validation and commercialization. “This collaboration reflects Servier’s commitment to applying cutting-edge technologies to address unmet medical needs and improve patient outcomes,” said Christophe Thurieau, Executive Director of Research at Servier. “We have full confidence in Insilico’s internally developed and validated AI platform, and this partnership marks a significant step forward in our shared mission to innovate in oncology.” Alex Zhavoronkov, PhD, founder, CEO, and CBO of Insilico Medicine, said, “This collaboration is a strong validation of our AI capabilities and R&D excellence. As we continue to embed generative AI into every stage of the pharmaceutical value chain, we are moving closer to a future where AI agents can autonomously make decisions, design experiments, and drive a virtuous cycle of faster, smarter, and safer drug development—what we call pharmaceutical superintelligence.” Insilico has a well-established track record in AI-driven oncology research. The company has built a robust pipeline targeting multiple cancer types, using both novel and well-validated biological mechanisms. Key candidates include ISM6331, a potential best-in-class pan-TEAD inhibitor, and ISM3412, a MAT2A inhibitor—both currently in global, multicenter Phase I clinical trials. Additionally, four other oncology programs have been partially or fully out-licensed to partners, with Phase I trials underway. Thanks to its advanced AI and automation technologies, Insilico has dramatically accelerated preclinical drug discovery. While traditional drug discovery typically takes an average of 4.5 years from concept to preclinical candidate nomination, Insilico has nominated 20 preclinical candidates between 2021 and 2024. On average, each program—from initiation to candidate nomination—takes just 12 to 18 months, with only 60 to 200 molecules synthesized and tested per project. Insilico Medicine is a pioneering biotechnology company dedicated to integrating AI and automation to accelerate drug discovery and advance health longevity. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under stock code 03696.HK. By combining deep in-house expertise with AI innovation, Insilico is developing novel therapies for unmet medical needs in fibrosis, oncology, immunology, pain, obesity, and metabolic disorders. The Pharma.AI platform also extends beyond pharmaceuticals into advanced materials, agriculture, nutritional products, and veterinary medicine. For more information, visit www.insilico.com.